Skip to main content
S&P 5007,743.41+0.51%DOW51,828.62+0.93%NASDAQ27,068.72+0.48%BTC$83,896.00-0.86%ETH$2,687.00-0.12%GOLD$4,320.50+0.52%OIL$92.44-2.29%
Smart Investors Daily
NT

NASDAQ · NTRB

Nutriband Inc.

Healthcare · Biotechnology

$8.00

Down-$0.99 (-11.01%)

Updated Sep 26, 2026, 3:10 AM

SID Score

5.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
56.14M
P/E ratio
-5.5
Dividend yield
0.00%
52-week range
$2.80 – $9.00
Volume
409.99K
Avg. volume
33.63K

Price performance

NTRB price history

1M range · 20 trading sessions · Daily adjusted prices

NTRB closed at $8.00 after 20 trading sessions, up 79.37% for the selected period.

Last close
$8.00
Period change
+79.37%
Period low
$4.35
Period high
$8.99
Daily close
View OHLC price history
NTRB OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 25, 2026$9.09$9.1851$7.10$8.00409.99K
Sep 24, 2026$7.35$9.00$7.35$8.99387.88K
Sep 23, 2026$6.75$7.50$6.56$7.35129.73K
Sep 22, 2026$7.775$7.875$6.66$6.76319.6K
Sep 21, 2026$8.21$8.55$7.30$7.77135.1K
Sep 18, 2026$7.66$8.13$7.03$8.13110.51K
Sep 17, 2026$7.11$7.66$6.94$7.65102.85K
Sep 16, 2026$6.87$7.05$6.69$7.0444.73K
Sep 15, 2026$6.85$7.05$6.72$6.8245.56K
Sep 14, 2026$6.92$7.04$6.521$6.925108.63K
Sep 11, 2026$6.18$6.9699$6.09$6.9699.83K
Sep 10, 2026$5.76$6.70$5.63$6.08112.11K
Sep 9, 2026$6.15$6.15$5.61$5.8039.04K
Sep 8, 2026$6.08$6.4658$5.46$6.10109.69K
Sep 4, 2026$5.66$6.07$5.17$5.9796.19K
Sep 3, 2026$4.72$5.92$4.72$5.63170.53K
Sep 2, 2026$4.53$4.79$4.50$4.7029.31K
Sep 1, 2026$4.33$4.48$4.2701$4.34518.66K
Aug 31, 2026$4.46$4.46$4.2197$4.36725.82K
Aug 28, 2026$4.66$4.7254$4.43$4.466.77K

Latest NTRB news

The latest Smart Investors Daily articles mentioning NTRB.

Stock researchCompany · Overview

NTRB research

Overview

Company profile and research snapshot.

Company profile

Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
NTRB recent ratings
DateFirmRatingTarget
Jan 22, 2025Noble Capital MarketsOutperform—
Jul 26, 2022Small Cap Consumer ResearchBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 22, 2026

Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing

ORLANDO, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) confirmed today that its outstanding warrants (NASDAQ:NTRBW) will expire on September 30, 2026 at 5PM ET as scheduled. The Company will not extend the expiration date and will not reprice the warrants. Warrant holders may exercise at the current strike price of $6.43 per share until the expiration date. Warrants not exercised by that date will expire in their entirety and be removed from the NTRBW Nasda

Yahoo · Sep 9, 2026

Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit

ORLANDO, Fla., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO, Gareth Sheridan will attend the inaugural Nasdaq LaB Biotech Summit on September 16th. The Summit brings together biotechnology executives, investors, and industry leaders for an evening of thought leadership and networking at Nasdaq MarketSite in New York. About AVERSA™ Abuse-Deterrent Transdermal Technology Nutriband's AVERSA™ abuse-deterrent transdermal technology incorp

Yahoo · Sep 8, 2026

Nutriband Receives USPTO Notice of Publication of Commercial Brand Name Trademarks for Its Abuse Deterrent Fentanyl Patch

Nutriband has received a Notice of Publication from the United States Patent and Trademark Office (USPTO) for commercial brand name trademarks for its lead product, an abuse deterrent fentanyl transdermal system. Once allowed, Nutriband plans to submit its commercial worldwide brand name to the FDA and other international regulatory agencies for approval. ORLANDO, Fla., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), a company engaged in the development of prescrip

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By